Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
US2021048442A1
Method for the characterization of peptide:mhc binding polypeptides
US2021032370A1
Recruiting agent further binding an mhc molecule
CL2020000988A1
New peptide from seq id no: 160 for use in immunotherapy against lung cancer, including small cell lung cancer and other cancers (divisional application no. 201701819)
PH12020500095A1
Improved dual specific polypeptide molecule
TW202039535A
Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
TW202024121A
Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
US2020087363A1
B*44 restricted peptides for use in immunotherapy against cancers and related methods
DE102019121007A1
Antigen binding proteins that specifically bind to MAGE-A
DE102019121022A1
Recruiting agent that also binds an MHC molecule
JP2020014460A
Novel immunotherapy for several tumors of blood, in particular chronic lymphatic leukemia (cll)
TW202019955A
Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods
IL267131D0
Novel t cell receptors and immune therapy using the same
PH12019501243A1
T cell receptors with improved pairing
US2019321478A1
T cell receptors and immune therapy using the same
TW202016131A
Peptides for use in immunotherapy against cancers
AR115254A1
PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER
PH12019500312A1
T cell receptors and immune therapy using the same
US2019192567A1
Peptides and combination of peptides for use in immunotherapy against various cancers
WO2019086665A1
Novel engineered t cell receptors and immune therapy using the same
